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ABSTRACT
Purpose: Ovarian cancer (OC) is the most lethal gynaecological cancer. Early 
detection is required to improve patient survival. Risk estimation models were 
constructed for Type I (Model I) and Type II (Model II) OC from analysis of Protein 
Z, Fibronectin, C-reactive protein and CA125 levels in prospectively collected samples 
from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Results: Model I identifies cancers earlier than CA125 alone, with a potential 
lead time of 3-4 years. Model II detects a number of high grade serous cancers at an 
earlier stage (Stage I/II) than CA125 alone, with a potential lead time of 2-3 years 
and assigns high risk to patients that the ROCA Algorithm classified as normal. 
Materials and Methods: This nested case control study included 418 individual 
serum samples serially collected from 49 OC cases and 31 controls up to six years 
pre-diagnosis. Discriminatory logit models were built combining the ELISA results for 
candidate proteins with CA125 levels.
Conclusions: These models have encouraging sensitivities for detecting pre-
clinical ovarian cancer, demonstrating improved sensitivity compared to CA125 alone. 
In addition we demonstrate how the models improve on ROCA for some cases and 
outline their potential future use as clinical tools.
INTRODUCTION
The estimation of cancer risk has the potential to 
improve patient survival through earlier diagnosis and 
treatment.  This approach may prove especially beneficial 
in ovarian cancer (OC) which is largely asymptomatic in the 
early stages. OC can be classified as either Type I or Type II. 
Type I OC includes low grade serous, endometrioid, clear 
cell, and mucinous carcinomas which are generally indolent, 
relatively genetically stable and lack TP53 mutations. 
Type II OC includes high-grade serous and endometrioid, 
undifferentiated carcinomas and carcinosarcomas that 
are highly aggressive, evolve rapidly and display TP53 
mutations in over 80% of cases [1, 2]. The majority of OC 
cases are diagnosed at a late stage, resulting in high case 
fatality. The overall 5 year survival for Stage III & IV is 
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only 23%, making this the most lethal of the gynaecological 
cancers [3–5]. When detected early prognosis is much 
better, with approximately 90% of women diagnosed at 
Stage I surviving five years or more [5]. 
Therefore, there is a clinical need to develop 
strategies which can detect OC early. Serum biomarkers are 
attractive targets for early detection protocols and CA125 
has been widely used in screening trials [6–11]. CA125  has 
limitations of specificity for OC as elevation in serum can 
also occur in pregnancy, endometriosis and menstruation 
[12]. Panels of biomarkers are thought to offer the potential 
for higher discriminatory power. However, recent studies 
which constructed putative biomarker panels with samples 
from the Prostate, Lung, Colorectal and Ovarian (PLCO) 
cancer trial found no improvement in diagnostic power in 
pre-clinical samples [7, 13] leaving CA125 as the single 
best biomarker for OC screening. To improve outcomes for 
OC patients there is a necessity to identify new biomarkers 
and develop risk models, algorithms and clinical protocols 
that are capable of improving on or complementing CA125 
for early detection of OC [14]. Such biomarkers can only 
be identified with initial discovery work carried out in 
prospectively collected sample sets. 
This study has developed two risk based models for 
the early detection of OC. The aim is to assess their utility 
in comparison to the best current biomarker, CA125, 
and to see if they can improve on the Risk of Ovarian 
Cancer Algorithm (ROCA).  The serum samples used in 
this study came from the UKCTOCS cohort of 202,638 
women [9, 15, 16]. This sample set  contained serial pre-
clinical samples for 50,000 of these women providing a 
unique opportunity for pre-clinical biomarker discovery 
targeting early stage OC. The models were constructed 
by analysis of the concentrations of putative biomarkers; 
Protein Z, and   Fibronectin both of which were recently 
identified as  putative biomarkers for ovarian cancer 
[17]. In conjunction with C-reactive protein, identified as 
a potential OC marker from the literature [18, 19]. The 
biomarkers (Protein Z, Fibronectin, C-reactive protein) 
were combined with CA125, in a nested case-control 
study within UKCTOCS to determine if a model including 
four markers would outperform CA125/ROCA-alone. 
The first, Model I was able to detect Type I whilst the 
second, Model II was able to detect Type II OCs. The 
success of the new models to improve over and above 
CA125 and ROCA are measured through several metrics: 
the enhanced discrimination between cases and controls, 
the earlier detection of cases (increased lead time), and in 
improved sensitivity. 
RESULTS
Construction of predictive models
The diagnostic potential of the panels of biomarkers 
were investigated by building separate logistic prediction 
models (logit models) for Type I (Table 1) and Type II 
(Table 2) OC cases. When analysing the sensitivity and 
specificity of the models ROC curves were constructed 
for investigation over two time ranges 0-1 years tDx and 
1-2 years tDx. 
Model I, was trained to identify Type I OC cases. 
The model (Table 1) included protein expression of 
CA125, Fibronectin and Protein Z, age of the women at 
sample collection and interaction terms between each of 
the proteins: Fibronectin and Protein Z, with age. 
Model II, was trained to identify Type II OC 
cases. The model (Table 2) included protein expression 
of CA125, Fibronectin and CRP, age of the women 
at sample collection and interaction terms between 
Fibronectin with age. 
Validation of models by leave-one-out cross 
validation
The models were assessed for overfitting using 
established methodologies for sample sets of this size 
in ovarian cancer research [20–22] using leave-one-out 
cross validation. Samples from each subject in turn were 
excluded from the dataset; the model retrained and logit 
scores predicted for excluded samples. The root mean 
square errors between logit scores predicted for samples 
from models built with them excluded from the model, 
against the complete model, were 0.024 for Type-I and 
0.020 for Type-II demonstrating that the models are 
not overfitted and are robust to exclusion of subsets of 
samples.
Improved descriptive power of models compared 
to model for CA125 alone 
Likelihood ratio tests comparing Model I and Model 
II with nested logit models constructed for CA125 alone 
(logit
CA125
) comparing residual variance using the chi 
square test showed both models fit the data better than 
CA125 alone (Type-I P < 2 × 10-07; Type-II P = 0.018).
Epidemiological factors do not add to models
Likelihood ratio tests comparing expanded 
versions of Model I and Model II, to include additional 
epidemiological factors of BMI and use of the 
contraceptive pill or hormone replacement therapy as 
determined at recruitment, were no better at describing 
the data (Model I P = 0.56 Model II P = 0.051). The 
borderline significant reduction in residual variance in the 
expanded version of Model II was due to contraceptive pill 
use. Lower pill use in the OC cases compared to controls 
in this sample may reflect the known protective effect 
of the pill, crucially the biomarkers are not correlated 
with pill use and so not a biological proxy for a readily 
available epidemiological factor.
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Evaluation of model performance compared to 
CA125 alone
The serial samples span a timeframe up to six years 
pre-diagnosis of OC, this enabled us to analyse both time 
course changes in our Model scores with that of CA125 
alone (the best current biomarker) and ROCA for OC 
cases and to compare Model scores for OC cases with 
those for controls (Figure 1). Lowess linear regression 
analysis of these plots show a much more dramatic shift in 
CA125 velocity within Type II OC subjects (Figure 1 IIA) 
compared to Type I (Figure 1 IA), whilst the controls show 
consistently low and flat expression for the respective 
Model scores across the time course. 
In some control samples (Figure 1 IC and IIC) the 
levels of the markers have shown an increase in risk (a 
Model score closer to 1), however these levels then 
decrease towards the normal range in subsequent serial 
samples. This is consistent with what is seen in the clinical 
setting. By comparison, in true OC cases (Figure 1 IB and 
IIB) when an individual demonstrates an elevation in risk, 
typically this risk continues to increase in subsequent 
serial samples. 
Increased lead time over CA125 alone
Lowess analysis on the OC cases plots (Figure 1 IB 
and IIB) demonstrates that for Type I the inflection point 
in the lowess analysis is about 1000 days (~3 years) time-
to-diagnosis (tDx), and for Type II the inflection point in 
the lowess analysis is ~800 days (~2 years) tDx, these 
precede the inflection points seen with the CA125 levels 
alone which occur at about 400 days (~1 year) tDx. 
Model I outperforms CA125 and ROCA
Area under the curve analysis
ROC curve analysis on samples (Figure 2) was 
carried out for Model I, CA125 alone (logit
CA125
) and 
the ROCA algorithm risk classification, at one year 
(Figure 2A) and two years pre-diagnosis (Figure 2B) 
in order to ascertain if the model improved detection in 
the patient population. For Type I less than one year tDx 
(Figure 2A) Model I AUC, 0.949 (95% CI 0.917-0.982), 
was significantly better than the ROCA AUC, which was 
0.857 (95% CI 0.776-0.939, P = 0.021), and at one to two 
years tDx (Figure 2B), its AUC of 0.808 (95% CI 0.684–
0.933) was significantly better than  ROCA with AUC of 
0.550 (95% CI 0.448-0.653 P < 1 × 10-3)  In both cases 
Model I gave a higher AUC than logit
CA125
 alone although 
in neither case was this significant.
The improvement in risk estimate provided by 
Model I can be further understood by comparing the 
risk score for each sample as predicted by Model I 
against logit
CA125
 (Figure 2C) and ROCA classifications 
(Figure 2D). The majority (119 of 145) of control samples 
have lower scores in Model I compared to that for CA125 
which confirms the model’s superior discriminatory power 
for the separation of OC cases and control. For Model I a 
high number of OC cases approaching diagnosis have logit 
scores near unity (1.0). At 98% specificity, of the 85 Type 
Table 1: Model I, with coefficients for each variable, the standard error of the estimate and P value
Coefficient Standard Error P value LOO Standard Deviation
(Intercept) −3.53 1.25 0.005 0.28
CA125 3.74 1.32 0.005 0.35
PROZ 2.90 1.30 0.026 0.31
FINC −1.50 0.89 0.093 0.31
Age 0.01 0.08 0.948 0.03
PROZ × Age −0.67 0.22 0.003 0.06
FINC × Age 1.21 0.45 0.007 0.12
Table 2: Model II, with coefficients for each variable, the standard error of the estimate and P value 
Coefficient Standard Error P value LOO Standard Deviation
(Intercept) −1.85 0.58 0.001 0.13
CA125 2.53 0.66 0.000 0.13
Age −0.02 0.09 0.816 0.02
FINC 0.53 0.41 0.197 0.10
CRP 0.59 0.32 0.065 0.05
FINC × Age 0.26 0.11 0.023 0.02
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I samples, Model I (score > 0.96) detected 27 samples 
from 11 (64%) women, at the same specificity logit
CA125 
(score > 0.74) detected 17 samples from 8 (47%) women 
(Figure 2C). The cases identified by Model I include 3 
endometriod, 5 serous, 2 clear cell and 1 adenocarcinoma 
whereas the cases identified by logit
CA125
 include 4 
endometriod, 2 serous and 2 clear cell. Of these individuals 
Model I identified 10 diagnosed at stage I and 1 at stage II 
whereas logit
CA125
 identified 7 diagnosed at stage I and 1 at 
stage 2. Thus Model I is capable of identifying more OC 
cases, particularly at stage I, than logit
CA125
.
Model score lead time comparison
The improvement in lead time achieved by Model 
I over logit
CA125
 is further illustrated by comparing the 
cumulative detection of cases over time approaching 
diagnosis, by finding the earliest in an unbroken chain of 
OC cases crossing the 98% threshold of the model from 
the samples closest to diagnosis (Figure 3A). This shows 
the 11 women with Type I OC are detected substantially 
earlier than by logit
CA125
. 
Model II outperforms logit CA125 and ROCA
Area under the curve analysis
The ROC curve analysis for Type II OC (Figure 4A) 
demonstrated that Model II was comparable to both 
logit
CA125 
and ROCA, less than one year tDx with AUCs of 
0.944, 0.926 and 0.950 respectively. Similarly for one to 
two years to diagnosis (Figure 4B) the AUCs were 0.638, 
0.546 and 0.669 respectively. As with Model I the majority 
of controls (99 of 145) are given lower scores by Model 
II than for CA125 alone which confirms this model’s 
superior discriminatory power for the separation of OC 
cases and control. 
Model II risk estimates are consistently higher 
than logit
CA125 
risk estimates, demonstrating the models 
superiority. Within the model scores Type II OC cases 
(Figure 4C, coloured symbols) were given higher scores 
than logit
CA125
 particularly as they approach diagnosis. At 
a specificity of 98% (0.76 logit score), of the 158 Type II 
samples, Model II detected 54 samples from 24 women 
(16 with high grade serous, 3 with endometrioid, 3 
Figure 1: Risk models outperform CA125 for Type I and Type II ovarian cancer. (I) Analysis of Type I ovarian cancer patients 
(IA) Loess linear regression analysis of trends in CA125 levels in Type I subjects. The grey shaded areas represent a moving estimate of 
the 80% percentile range of expression. The thick black line represents the trend in the data identified by the Lowess analysis. (IB) Lowess 
linear regression analysis of the Model I for Type I subjects. Ovarian cancer patients are represented by circles and individual patient levels 
over time are shown by connected circle. The thick black line represents the trend in the data identified by the Loess analysis. Notice the 
dramatic and sequential rise in risk estimate as Type I subjects approach diagnosis. (IC) Lowess linear regression analysis of Model I for 
control subjects. Control patients are represented by circles and individual patient levels over time are shown by connected circle. The 
thick black line represents the trend in the data identified by the Lowess analysis. (II) Analysis of Type II ovarian cancer patients (IIA) 
Lowess linear regression analysis of trends in CA125 levels in Type II subjects. The grey shaded area represents a moving estimate of the 
80% percentile range of expression. The thick black line represents the trend in the data identified by the Lowess analysis. (IIB) Lowess 
linear regression analysis of Model II for Type II subjects. Ovarian cancer patients are represented by circles and individual patient levels 
over time are shown by connected circle. The thick black line represents the trend in the data identified by the Loess analysis. Notice the 
dramatic and sequential rise in risk estimate as Type II subjects approach diagnosis. (IIC) Lowess linear regression analysis of the Model II 
for control subjects. Control patients are represented by circles and individual patient levels over time are shown by connected circle. The 
thick black line represents the trend in the data identified by the Lowess analysis.
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with adenocarcinoma and 2 with papillary serous 
cystadenocarcinoma OC). Whereas at the same 98% 
specificity logit
CA125
 (score > 0.72) detected 43 samples 
from 22 women (15 with high grade serous, 2 with 
endometrioid, 3 with adenocarcinoma and 2 with papillary 
serous cystadenocarcinoma OC). 
Model score lead time comparison
Within the additional 11 samples detected at 98% 
specificity by Model II, one was an additional high grade 
serous and endometrioid case diagnosed at Stage III that 
were previously missed by logit
CA125
. It can also be seen 
that the 24 women are detected earlier by Model II than 
by logit
CA125
 (Figure 3B). 
Comparison with ROCA (Figure 4D) shows five 
high grade serous OC samples from a single woman and 
one high grade endometriod (red and blue symbols) which 
Model II identified by high scores (Figure 4D) which were 
previously classified as “normal” by ROCA. Both these 
cancers were diagnosed at stage III. The endometriod 
cancer was not diagnosed in the time covered by our 
sample set (6 years). The serous case was first identified by 
ROCA 140 days tDx, whereas every single sample in our 
sample set for this individual crossed the 99th percentile 
threshold for Model II, from 501 days tDx and as far out 
Figure 2: Model I performance compared to CA125 and ROCA. (A) Type-I ROC curves for less than one year tDx. (B) Type-I 
ROC curves for one to two years tDx. (C)  Comparisons between Model I scores and logit
CA125
. (D) Comparisons between Model I scores 
and ROCA.
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as 2008 days tDx. Perhaps representing the detection of 
a cancer developing slowly through stage I and II over a 
number of years. This demonstrates the power of Model II 
to detect OC cases that the ROCA approach either detects 
later or importantly does not detect.
Risk models as triage tool for symptomatic 
women
The models as outlined above are suitable for 
application in a screening programme context where they 
require an initial sample to be taken against which velocity 
of change in protein expression may be calculated. 
A potential alternative application of this biomarker 
panel, once it has undergone further validation, would be 
as a triage tool for clinicians to assess, from a single blood 
sample, whether a symptomatic patient is at low or high risk 
of OC. In this context it may be a useful tool on its own or 
potentially in combination with current protocols used for 
differential diagnosis of an adnexal mass in symptomatic 
patients such as OVA1[23] or ROMA [10, 24]. 
Within the current study we cannot directly compare 
the advantages and disadvantages of our results with 
ROMA and or indeed OVA1 , as stated above both were 
designed for differential diagnosis of an adnexal mass 
in symptomatic patients. The UKCTOCS study was not 
directed at symptomatic high risk populations but rather 
as a general screening tool. 
However, given that OVA1[23] and ROMA [10, 24] 
algorithms give significant weighting to CA125 levels, 
our models can be adapted (as described in methods) and 
assessed to ascertain, if from the measurement of a single 
sample, they can improve on CA125 alone.
To test this we combined the models (Supplementary 
Figure S1) into a schema in which a threshold was set for 
each model, setting the specificity at > 98% for that model 
(logit score 0.90  for Model I and 0.77 for Model II), so 
that should a patient sample exceed the specified threshold 
on either model, they would be considered at high risk of 
OC. A follow up sample could then be taken and if the risk 
was still high they could be sent for further investigations, 
for example, transvaginal ultrasonography (TVS).
The performance of the triage algorithm 
(Supplementary Figure S1) was assessed by comparing 
the earliest in an unbroken chain of OC cases breaching 
either the Model I or Model II threshold, or the CA125 
clinical threshold of 35 U/mL (Figure 5) The results are 
presented as Type I vs CA125, Type II vs CA125 and as 
combined ovarian cancer (triage algorithm) vs CA125. In 
each comparison the model threshold protocol was able 
to identify OC cases earlier than CA125. The specificity 
of the protocol determined from all control samples was 
95%. The triage tool significantly outperforms CA125 
in terms of sensitivity particularly for Type II cases. The 
sensitivity of the algorithm compared to CA125 at 3, 6, 9 
and 12 months tDx are shown in Table 3 for Type I, Type 
II and combined ovarian cancer (triage algorithm).
DISCUSSION
Using serial samples from UKCTOCS, we 
developed two risk models that demonstrate superior 
Figure 3: Risk Models detect OC earlier than CA125-Plot showing the cumulative diagnosis of OC cases. (A) Model I 
diagnosis of Type I cases (grey) compared to logit
CA125
 (light grey). (B) Model II diagnosis of Type II cases (black) compared with logit
CA125
 
(light grey). Model I diagnoses cases substantially earlier than logit
CA125
. Model II diagnoses several samples earlier than logit
CA125
.
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clinical performance for OC risk prediction over CA125 
alone and ROCA. Leave-one-out analysis of models 
indicates the models are robust to sample exclusion and 
not over fitted to the dataset. Between them Models I and 
II incorporate four proteins: CA125, Protein Z, Fibronectin 
and C-reactive protein, and interaction terms between 
Protein Z and fibronectin with age. Of the four proteins 
CA125 is the current best biomarker used in clinical 
practise [6–11]. C-reactive protein is also known to be 
associated with ovarian cancer [18, 19] as well as having a 
general association with injury and infectious disease [25]. 
The role of Fibronectin and Protein Z in ovarian cancer is 
less well defined. Fibronectin provides a substrate in the 
extracellular matrix for cell adhesion and migration [26] 
Table 3: Table of sensitivities obtained for the triage algorithm for  Type I, Type II and combined 
OC cases for the indicated tDx
Sensitivity Models I and II Sensitivity logitCA125 
Month tDx Type I Type II Combined OC Type I Type II Combined OC
< 3 0.53 0.83 0.72 0.53 0.53 0.53
3–6 0.53 0.6 0.57 0.47 0.3 0.34
6–9 0.41 0.53 0.45 0.24 0.2 0.21
9–12 0.3 0.33 0.3 0.24 0.13 0.17
Figure 4: Model II performance compared to CA125 and ROCA. (A) Type-II ROC curves for less than one year tDx. (B) 
Type-II ROC curves for one to two years tDx. (C)  Comparisons between Model II scores and logit
CA125
. (D) Comparisons between Model 
II scores and ROCA.
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playing a critical role in healthy development and wound 
healing. It has been found in elevated concentrations in 
the vicinity of tumours including those of breast [27] and 
ovarian [28] cancer where its elevation indicates poorer 
prognosis, presumably because it facilitates cancer cell 
invasion of surrounding tissues [29]. 
Protein Z is part of the haemostatic system in which 
it supresses clot formation by deactivating factor X in 
combination with its partner protein Z protease inhibitor 
[30]. Haemostatic system inhibitors are known to play 
a role in determining the malignancy of cancers [31]. 
Protein Z has previously been found down regulated in 
patients diagnosed with acute leukaemia compared with 
controls [32], but has also been found to be upregulated in 
tissues of gastric [33], breast [34] and colon [35] cancers. 
It is possible the down regulation of serum Protein Z 
reflects sequestration to the tumour site where it may 
prevent coagulation. 
ROC, area under the curve, analysis confirms that 
Model I outperforms CA125 and ROCA in both specificity 
and sensitivity. Model I returns higher risk scores for OC 
cases and importantly it is able to identify some cases 
that either CA125 or ROCA detected later, or not at all. 
Lowess analysis demonstrates that the inflection point at 
which scores for women with Type I tumours start to rise 
is approximately 1000 days (~3 years) tDx, compared to 
400 days (~1 year) tDx for CA125 alone. Furthermore, the 
lowess trend for control subject scores does not rise. Model 
I can discriminate between OC cases and controls, and it 
does so earlier in the disease process than CA125 alone. 
The Type I model had better AUC than both ROCA and 
logit
CA125
, offering the potential to detect Type I OC cases 
with greater sensitivity and specificity than is currently 
possible, even one to two years tDx. When considering 
lead time, women enrolled in UKCTOCS were likely to 
be detected on average 1–2 years before they would have 
been clinically. Therefore, Model I potentially offers a lead 
time of 3 to 4 years for Type I OC.
Model II outperforms both CA125 and ROCA 
for the detection of Type II OC. Whilst the ROC curves 
suggest similar performance to a model based on CA125 
alone (logit
CA125
) and ROCA, crucially Model II returns 
higher risk scores for OC cases and importantly it is 
able to identify some cases that either CA125 or ROCA 
detected later. Comparisons of Model II and logit
CA125 
scores show Model II assigns higher scores, and is 
therefore more confident in its identification of a set of 
54 samples from 24 women (16 with high grade serous, 
3 with endometrioid, 3 with adenocarcinoma and 2 with 
papillary serous cystadenocarcinoma OC) with 6 of these 
diagnosed at stage I and 7 at stage II. 
Cumulative diagnostic plots show Model II 
consistently identifies cases earlier than logit
CA125
. Lowess 
analysis demonstrates that the inflection point where 
Figure 5: Risk Models detect OC earlier than CA125 in triage algorithm- Plot of the cumulative diagnosis of OC 
cases using the triage algorithm. (A) Type I cases only (grey), (B) Type II cases only (grey) and (C) Combined OC cases (grey), 
plotted against the CA125 > 35 U/mL clinical threshold (light grey). For Type I cases the algorithm identifies many more samples at much 
earlier time points. For Type II cases the algorithm also detects OC cases much earlier than the CA125 threshold. The patterns continue for 
combined OC.
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scores for women with Type II tumours start to rise is 
approximately 800 days (~2 years) tDx, compared to 
400 days (~1 year) tDx for CA125. Furthermore, the 
lowess trend for control subject scores shows near flat 
expression. Significantly, Model II can discriminate 
between OC cases and controls and it does so earlier 
in the disease process than CA125 alone and therefore 
potentially offers a lead time of 2 to 3 years pre-diagnosis.
The comparison with ROCA is more problematic 
as the OC cases in the UKCTOCS study were identified 
by this method, which means that the sample population 
almost certainly overestimates ROCA’s performance 
in a general population. This is substantiated by the 
greater ROCA AUC observed at less than one year prior 
to diagnosis for our sample set 0.950 (95% CI: 0.914–
0.986) compared with that of the entire UKCTOCS trial 
dataset 0.915 (95% CI: 0.883-0.946). Despite this, a 
similar discrimination is seen for the Type II cases when 
comparing Model II with ROCA as was seen for the 
comparison with CA125 alone.
For Model II, 6 OC samples, 5 high grade serous 
(serial samples from a single case) and one endometriod, 
were classified as ‘normal’ by ROCA. However, these 
cases were given high scores by Model II indicating that 
for some aggressive OC cases Model II has the potential 
to detect them earlier than ROCA. Within Model II a 
small number of control samples were assigned elevated 
scores. This would not be problematic in a screening 
context, as one can see from the serial analysis of these 
control samples that their levels return to normal after 
a single elevated score. However, for OC patients once 
there is an increase in the score this continues to rise in 
subsequent serial samples. This would be accommodated 
in a screening protocol by having a follow up confirmatory 
sample.
Both Models demonstrate the potential for use as 
triage tools for women presenting with symptoms of OC 
or a pelvic mass (Supplementary Figure S1). The models 
could be used either on their own or in combination 
with established algorithms such as OVA1 or ROMA. A 
high risk score on either model would result in a follow 
up sample being taken if this was still high then further 
investigation for suspected OC should follow; a low risk 
score would encourage the clinician to consider alternative 
diagnoses. 
We have developed two risk models based on 
panels of serum biomarkers that outperform CA125 in 
the detection of both Type I and Type II OC. Model II 
identifies the biologically aggressive Type II OC at an 
earlier stage than CA125 alone, offering the potential 
for earlier diagnosis and improved survival for women 
with this poor prognosis disease. The panels proposed 
here, whilst impressive, require further validation in a 
larger, independent sample set, containing samples from 
patients with benign ovarian tumours and other diseases in 
order to add confidence in their utility as screening tools. 
However, in the current context they add significantly to 
the knowledge in the field of early detection biomarkers 
for OC and move us closer to the identification of 
biomarker panels and risk models for the early detection 
and diagnosis of OC. 
MATERIALS AND METHODS
Study population
This study analysed 418 prospectively collected 
serial serum samples from women in the UKCTOCS 
[9, 15, 16] (ISRCTN22488978; NCT00058032), a 
randomised control trial designed to assess the effect of 
screening on mortality[15]. Over 202,000 women from 13 
centres across the UK were recruited and separated into 
three cohorts for investigation. The research presented 
here used serum samples collected from women in the 
multimodal screening arm of UKCTOCS, which consisted 
of > 50,000 women who had serial serum samples taken 
over a ten year period. UKCTOCS also collected detailed 
epidemiological data from health questionnaires and 
clinical data for OC cases including tumour classification, 
morphology and stage at diagnosis. 
The serum set investigated here comprised eighty 
women from the multimodal group of UKCTOCS; 
49 diagnosed with invasive epithelial (9 Type I and 30 
Type II) and borderline (10) (as with previous studies we 
grouped borderline tumours with Type I for analysis) [17, 
36-38] and thirty one controls matched to the Type II OC 
cases by age, collection centre and date. A study design 
flowchart is presented for this cohort in Supplementary 
Figure S2  and information on baseline characteristics 
can be found in Table 4 and Supplementary Table S1 
[17]. This set contained all of the invasive ovarian cancer 
samples available that had serial samples spanning less 
than 14 months to diagnosis right through to greater 
than 32 months and up to 72 months to diagnosis. Two 
control women were excluded because they went on to 
develop either skin or breast cancer. One Type I sample 
was excluded because only two samples were available 
so that only a single sample was available after scaling 
to the first sample. A second Type I subject was removed; 
as the single example of Papillary serous cystadenoma 
borderline malignancy in the sample set it was diagnosed 
at stage Ia and did not display any elevation in CA125 and 
therefore effectively behaved as a control over the time 
window of analysis.
ELISA assays
Candidate biomarkers: Fibronectin and C-reactive 
protein (uniprot accession numbers: P02751 and P02741 
respectively) were quantified in all 418 serum samples by 
ELISA kit assays (Abcam, Cambridge, UK) according to 
manufacturer’s instructions, duplicate readings, average 
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CV’s were 5% and 4.3% respectively. Protein Z serum 
values (uniprot accession numbers: P22891) for all 
samples were available from a study we recently carried 
out [17]. Serum CA125 levels were available as part of 
UKCTOCS for the set as previously described [9].
ROCA classification
CA125 results within UKCTOCS were interpreted 
using the ROCA algorithm [11, 39]. All women randomised 
to the multimodal group of the trial underwent annual 
CA125 testing and based on the ROCA classification, they 
were either returned to annual screening (if their risk was 
normal) or triaged to repeat CA125 testing in three months 
(if intermediate risk) or repeat CA125 and transvaginal 
ultrasound in six weeks (if elevated risk) [9, 15, 16]. 
Those with persistently elevated risk were sent for clinical 
assessment with a view to surgery. The trial protocol is 
detailed elsewhere [9, 15, 16].
Data analysis
Data was processed, analysed, and figures produced 
using the R (3.2.4) statistical environment (www.r-project.
org), all P values are two-sided. All protein abundances 
were normalised to that of the earliest collected sample (as 
with established biomarker longitudinal analysis (ROCA 
[8]), velocity rather than absolute levels of biomarkers 
were the basis of models), log transformed and scaled to 
unit variance. In order to keep variables at comparable 
magnitudes the age of the women at sample collection was 
rescaled by subtracting the median age in the data set. The 
controls were matched to the Type II OC cases by age, 
collection centre and date. As controls do not have a time 
to diagnosis, for comparison with cases, samples from the 
control women were allocated a tDx value so that the last 
sample for each control was matched to the last sample 
from the matched case.
Logit regression returns the probability that a given 
subject is a case rather than a control. Here separate 
multivariable logistic regression models for Type I and 
Type II OC cases against the shared controls were built 
to assess the additional contribution candidate biomarkers 
might make as part of a diagnostic panel. 
For each OC type a logit model was trained on OC 
cases less than 400 days to diagnosis, (chosen as this 
was the point at which CA125 began to elevate in OC 
cases), against matched controls, by analysis of the levels 
of the putative biomarker panel and selected interactions 
between age and panel members.
The models were assessed for overfitting using 
established methodologies for sample sets of this size in 
ovarian cancer research [20–22], by leave-one-out cross 
validation. This confirmed the stability of the model’s 
coefficients and the logit odds of the excluded samples. 
Models were compared with nested alternatives 
by likelihood ratio tests of the residual variance with 
the chi-squared test. The improved descriptive power 
of the putative panel over CA125 alone was confirmed 
by eliminating all terms bar CA125 from Models I 
and II. The possibility that the epidemiological factors 
such as body mass index (BMI), hormone replacement 
therapy (HRT) or the contraceptive pill affected the 
model was excluded by training an expanded version 
of each of model I and model II which included these 
epidemiological factors.  
Table 4: Information on the OC sample population used within the study including, type, 
morphology and stage at diagnosis
Number
Cancer Type All Stage I Stage II Stage III
Type I 19 16 2 1
 Borderline 10 10 . .
  Serous 6 6 . .
  Mucinous 2 2 . .
  Endometrioid 2 2 . .
 Invasive 9 6 2 1
  Low grade endometrioid 5 3 1 1
  Clear cell 3 2 1 .
  Adenocarcinoma 1 1 . .
Type II 30 7 8 15
High grade serous 23 5 6 12
High grade endometrioid 3 1 1 1
Carcinosarcoma 1 . . 1
Adencarcinoma 3 1 1 1
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Predictive power of the biomarker panel models 
in terms of specificity and sensitivity was compared 
with ROC curve analysis against the UKCTOCS ROCA 
classification and prediction based on CA125 levels alone 
using the pROC package in R [40] for the time periods 
0–1 years tDx and 1–2 years tDx.   
A ‘potential future’ alternative application of this 
biomarker panel may be as a triage tool for clinicians to 
assess, from a single blood sample, whether a symptomatic 
patient is at low or high risk of OC. The models outlined 
above were adapted for this purpose, by normalising the 
expression of each protein to the median level observed 
in the controls, rather than the initial sample taken from a 
subject, producing a model applicable to a single sample, 
such as would be obtained in primary care. The models 
were again trained as outlined above.
Cumulative diagnostic plots were created by 
plotting accumulated diagnosis against tDx. In order to 
exclude false positive diagnosis that might inflate the 
diagnosis rate, an unbroken chain of positive diagnosis 
were required between a positive diagnosis and the last 
two samples acquired prior to diagnosis.
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